Olezarsen reduces all-cause health services utilization and improves the treatment experience of patients with familial chylomicronemia syndrome
Open Access
- 19 December 2025
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (2) , 299-309
Abstract
No abstract availableKeywords
Funding Information
- Ionis Pharmaceuticals
This publication has 24 references indexed in Scilit:
- Patient experience with familial chylomicronemia syndrome before and after olezarsen treatment: Qualitative interviews with clinical trial participantsJournal of Clinical Lipidology, 2025
- Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practiceJournal of Clinical Lipidology, 2025
- Recurrence rates and risk factors for recurrence after first episode of acute pancreatitis: A systematic review and meta-analysisEuropean Journal of Internal Medicine, 2023
- Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administration–Approved Labeling, 2009 to 2019Value in Health, 2021
- Genetic testing in dyslipidemia: A scientific statement from the National Lipid AssociationJournal of Clinical Lipidology, 2020
- Chylomicronemia syndrome: Familial or not?Journal of Clinical Lipidology, 2020
- The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS studyJournal of Clinical Lipidology, 2018
- Acute Pancreatitis is Highly Prevalent and Complications can be Fatal in Patients with Familial Chylomicronemia: Results From a Survey of LipidologistJournal of Clinical Lipidology, 2016
- Hospitalizations In Hyperchylomicronemia Patients In Quebec, Canada; Results From A Real-World Observational StudyValue in Health, 2015
- Long-Term Costs and Consequences of Patients with Familial Chylomicronemia Syndrome – A Simulation Model ApproachValue in Health, 2014